Company profile
Annexon, Inc.
NASDAQ:ANNXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Tanruprubart | phase3 | — | 6 | completed, terminated |
| Vonaprument | phase2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04035135 | phase1 | completed | 2020-01-29 | 2021-05-19 | Annexon, Inc. | A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) |
| NCT04535752 | phase1 | completed | 2020-10-30 | 2021-06-26 | Annexon, Inc. | A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV) |
| NCT06510816 | phase3 | active_not_recruiting | 2024-07-30 | 2026-10-31 | Annexon, Inc. | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) |
| NCT04656561 | phase2 | completed | 2021-02-26 | 2023-03-28 | Annexon, Inc. | A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy |
| NCT05780515 | phase1 | completed | 2022-08-09 | 2023-08-31 | Annexon, Inc. | A Study of ANX009 in Adult Participants With Lupus Nephritis |
FDA applications (0)
No records yet.